•
AB
ABOS
Acumen Pharmaceuticals, Inc. Common Stock
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
112.67M
Volume
212.46K
52W High
$2.46
52W Low
$0.86
Open
$1.87
Prev Close
$1.86
Day Range
1.76 - 1.92
About Acumen Pharmaceuticals, Inc. Common Stock
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Latest News
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
GlobeNewswire Inc.•Nov 5
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Aug 26
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire Inc.•Aug 5
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
GlobeNewswire Inc.•Jul 10
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
GlobeNewswire Inc.•May 7
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire Inc.•May 6
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire Inc.•Apr 2
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report
GlobeNewswire Inc.•Mar 19